Voltron Therapeutics, Inc. Executes Manufacturing Agreement with Global Pharmaceutical Contract Development and Manufacturing...
September 16 2020 - 9:40AM
Voltron Therapeutics, Inc. today announced that it has executed a
manufacturing agreement for its vaccine portfolio with a global
pharmaceutical contract development and manufacturing organization.
The agreement partners Voltron with a multi-national company known
for enabling companies in the pharmaceutical, biotech and medical
device industries worldwide to advance discoveries and deliver
groundbreaking treatments to patients.
Today’s news comes on the heels of the Company’s announcement of
the successful completion of its first small animal safety and
immunogenicity study assessing the effect of novel vaccine Halovax™
against COVID-19. The vaccine construct was completed with positive
response to selected COVID-19 peptides in conjunction with the
self-assembling vaccine prototype. The study demonstrates that
selection algorithm for immunogenic peptides is functioning
appropriately.
HaloVax is being developed in conjunction with Hoth
Therapeutics, Inc. (NASDAQ: HOTH).
The company’s vaccines are built on a base of a heat shock
protein (HSP70) that activates the cellular portion of the immune
system; this is different from most other vaccine efforts, which
have used adjuvants such as alum. The second portion of the vaccine
consists of peptides derived from the target of the vaccine – which
can be a virus or a cancer patient’s tumor. These are bound
to the heat shock protein via Avidin and Biotin. This enables rapid
iteration and up-to-date data informed changes in the peptide
sequences to enable swift production of the vaccine.
“We are pleased to have executed a manufacturing agreement with
an international contract manufacturer for our vaccine portfolio.
This initiative builds atop our recent operational momentum,
including our recently announced successful preclinical testing of
our COVID-19 vaccine candidate. We are now actively moving toward
starting clinical trials in humans with the goal of bringing to
market proven and effective vaccines to help treat a range of
conditions, including various cancers and COVID-19,” said Pat
Gallagher, Chief Executive Officer, Voltron Therapeutics, Inc.
About Voltron Therapeutics, Inc.
Voltron Therapeutics, Inc., a Delaware corporation, was founded
in 2017 to lead and accelerate the development of the Vaccine and
Immunotherapy Center (VIC), and the Massachusetts General
Hospital’s novel Self Assembling Vaccine technology in a variety of
indications, including in Oncology and emerging Infectious
Diseases. Voltron holds an exclusive worldwide license to this
technology. With the work of our world class team of researchers
and physicians, this technology has shown in certain pre-clinical
studies initial proof of concept in two infectious diseases (Lassa
Fever and Q Fever) as well as two oncology indications (Ovarian and
HPV Related Cancers). For more information please visit
www.voltrontx.com.
About HaloVax™, LLC
HaloVax, LLC is a special purpose subsidiary of Voltron
Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc.
(NASDAQ: HOTH) The mission of HaloVax is to develop a novel,
Self-Assembling Vaccine against COVID-19, utilizing technology
licensed by Voltron Therapeutics, Inc. from the Vaccine and
Immunotherapy Center at the Massachusetts General Hospital. The
vaccine is being designed from a validated platform to provide
customized T cell immunity against COVID-19, as well as be able to
adapt rapidly to potential genetic drift of the virus. For more
information, please visit
www.HaloVax.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on developing new generation
therapies for dermatological disorders. Hoth’s pipeline has the
potential to improve the quality of life for patients suffering
from indications including atopic dermatitis, chronic wounds,
psoriasis, asthma and acne. To learn more, please
visit www.hoththerapeutics.com.
Forward Looking Statements
This press release includes “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release include, but
are not limited to, statements that relate to the advancement and
development of the VaxCelerate Platform, the commencement of
clinical trials, the availability of data from clinical trials and
other information that is not historical information. When used
herein, words such as “anticipate”, “being”, “will”, “plan”, “may”,
“continue”, and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Voltron’s current expectations and various
assumptions. Voltron believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
Voltron may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various important factors, including, without limitation, market
conditions and any Voltron filings made with the Securities and
Exchange Commission. Consequently, forward-looking statements
should be regarded solely as Voltron’s current plans, estimates and
beliefs. Investors should not place undue reliance on
forward-looking statements. Voltron cannot guarantee future
results, events, levels of activity, performance or achievements.
Voltron does not undertake and specifically declines any obligation
to update, republish, or revise any forward-looking statements to
reflect new information, future events or circumstances or to
reflect the occurrences of unanticipated events, except as may be
required by law.
Investor Contacts:
Matt Duffy President Voltron Therapeutics, Inc. 646-335-5923
mduffy@luciuspartnersllc.com
Jason Assad Investor Relations Voltron Therapeutics, Inc.
678-570-6791 jwassad@bellsouth.net
Hoth Therapeutics (NASDAQ:HOTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hoth Therapeutics (NASDAQ:HOTH)
Historical Stock Chart
From Apr 2023 to Apr 2024